Investor Relations

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 4:00 PM ET on Jul 25, 2014
Last Price Change Open Day High 52-Week High
0.42  down   (2.929%) 14.24 14.25 20.10
Volume Previous Close Day Low 52-Week Low
30,300 14.34 13.90 10.90

View all »   RSSRecent Releases

Jul 24, 2014
Esperion Therapeutics Announces Initiation of a Phase 2 Clinical Study of ETC-1002 in Patients with Hypercholesterolemia and Hypertension

Jul 16, 2014
Esperion Therapeutics to Host Inaugural Analyst and Investor Day

View all »Events & Presentations

Jul 29, 2014 at 8:30 AM ET
Esperion Therapeutics, Inc. Inaugural Analyst and Investor Day